Biogen Sets A High R&D Bar With A Pipeline That Extends Well Beyond MS

The company has recruited top talent and is studying some of the most challenging areas within pharma, including neurodegenerative and rare diseases, but the high-risk, high-reward nature of the pipeline has spooked some investors.